SCHEMBL3600570

SCHEMBL3600570

CCCN(CCC)C(=O)c1cccc(-c2nnc([C@@](C)(Cc3ccccc3)NC(=O)OC(C)(C)C)o2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.41
NPC1 O15118 6/20 0.41
RAB9A P51151 6/20 0.41
ALDH1A1 P00352 5/20 0.41
MAPT P10636 1/20 0.41
KDM4E B2RXH2 1/20 0.40
BACE1 P56817 5/20 0.37
CTSD P07339 2/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
TSHR P16473 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MEN1 O00255 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
TLR8 Q9NR97 1/20 0.36
HPGD P15428 3/20 0.36
CTSS P25774 2/20 0.35
CTSK P43235 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3600572 1.00 SMN1; SMN2 (0.41) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL8286008 0.90 BACE1 (0.38) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL3600929 0.86 BACE1 (0.35) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL3600932 0.86 BACE1 (0.35) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL8286686 0.84 BACE1 (0.36) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL3595013 0.84 BACE1 (0.34) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL3602904 0.84 BACE1 (0.34) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL3602907 0.84 BACE1 (0.34) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL3595017 0.84 BACE1 (0.34) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL3590345 0.82 BACE1 (0.53) SMN1; SMN2NPC1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740559-B1 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2014-10-15 EP disclosed
US-7847100-B2 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease Merck, Sharp & Dohme, Inc. (US) 2010-12-07 US disclosed
US-20070244119-A1 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease MERCK SHARP & DOHME LLC 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244119-A1 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease BACE1, BACE2, PSEN1 SMN1; SMN2 1431/4885NPC1 158/4885RAB9A 1858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.